ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Santen Pharmaceutical Co., Ltd.

Business Summary

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue249,605M2,353.48M
Gross Profit141,464M1,333.84M
Operating income38,651M364.43M
Income before tax12,776M120.46M
Net income6,826M64.36M
EBITDA55,843M526.53M
Diluted EPS17.050.16
Dividends Per Share280.26
Total Assets402,353M3,641.20M
Total liabilities95,305M862.48M
Total equity307,585M2,783.57M
Operating cash flow38,808M365.91M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 199,096M 224,942M 234,026M 241,555M 249,605M
Gross Profit 115,763M 129,618M 134,165M 134,703M 141,464M
Operating income 33,301M 38,637M 41,242M 40,125M 38,651M
Income before tax 30,055M 39,261M 43,117M 32,091M 12,776M
Net income 21,717M 35,247M 31,953M 23,616M 6,826M
EBITDA 43,183M 49,533M 52,211M 56,698M 55,843M
Diluted EPS 52.76 86.42 78.43 59.00 17.05
Dividends Per Share 26 26 26 27 28
Total Assets 358,906M 388,463M 391,186M 408,768M 402,353M
Total liabilities 102,977M 100,904M 98,614M 106,208M 95,305M
Total equity 255,110M 285,823M 290,900M 302,865M 307,585M
Operating cash flow 10,843M 42,843M 32,894M 39,947M 38,808M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,838.58M 2,029.56M 2,110.34M 2,221.69M 2,353.48M
Gross Profit 1,069.03M 1,169.49M 1,209.84M 1,238.92M 1,333.84M
Operating income 307.52M 348.60M 371.90M 369.04M 364.43M
Income before tax 277.54M 354.23M 388.81M 295.15M 120.46M
Net income 200.54M 318.02M 288.13M 217.20M 64.36M
EBITDA 398.78M 446.91M 470.81M 521.47M 526.53M
Diluted EPS 0.48 0.77 0.70 0.54 0.16
Dividends Per Share 0.24 0.23 0.23 0.24 0.26
Total Assets 3,220.90M 3,652.68M 3,534.22M 3,786.46M 3,641.20M
Total liabilities 924.14M 948.79M 890.94M 983.81M 862.48M
Total equity 2,289.41M 2,687.56M 2,628.17M 2,805.47M 2,783.57M
Operating cash flow 100.13M 386.55M 296.62M 367.41M 365.91M

Valuation Measures

Mar 2021
PER89.12
ROA1.68%
ROE2.23%
Operating margin15.48%
Profit margin2.73%

Key executives

  • President, CEO & Representative Director: Shigeo Taniuchi
  • CFO, General Manager-Finance & Administration: Kazuo Koshiji
  • Chief Information Officer, GM-Digital & IT: Minori Hara
  • Chief Compliance Officer & Executive Officer: Mika Masunari
  • Executive Officer: Kenji Morishima

Shareholders

  • MFS International (UK) Ltd. (4.8%)
  • Massachusetts Financial Services Co. (4.3%)
  • Mitsubishi UFJ Financial Group, Inc. (3.4%)
  • Nomura Asset Management Co., Ltd. (2.9%)
  • Nippon Life Insurance Co. (2.6%)
  • The Vanguard Group, Inc. (2.2%)
  • Ono Pharmaceutical Co., Ltd. (2.1%)
  • Eisai Pension Fund (1.7%)
  • BlackRock Fund Advisors (1.6%)
  • Black Creek Investment Management, Inc. (1.6%)

Contact Details

  • Website:http://www.santen.co.jp
  • Address: Grand Front Osaka Tower A, 25/F, 4-20 Ofuka-cho, Osaka, 530-8552, Japan
  • Phone: +81.6.7664.8621

Related Companies

  • Santen Pharmaceutical (Hong Kong) Ltd.
  • Phacor, Inc.
  • Santen Canada, Inc.
  • Santen Pharmaceutical Restricted Stock Compensation Plan
  • Santen Philippines, Inc.
  • Santen Pharma Malaysia Sdn. Bhd.
  • Santen (Thailand) Co., Ltd
  • Santen SA
  • Santen Eye Care Co., Ltd.
  • Santen Business Services Co., Ltd.
  • Claire Co., Ltd.
  • Santen Italy Srl
  • Santen Pharmaceutical Spain SL
  • SantenPharma AB
  • Santen India Pvt Ltd.
  • Santen Pharmaceutical Korea Co., Ltd.
  • Santen Pharmaceutical Asia Pte Ltd.
  • Santen Pharmaceutical Sales & Marketing (Suzhou) Co., Ltd.
  • Taiwan Santen Pharmaceutical Co., Ltd.
  • Santen SAS
  • Santen Pharmaceutical Trust
  • Santen Pharmaceutical (China) Co., Ltd.
  • Santen Holdings U.S., Inc.
  • Santen Pharmaceutical Pension Fund
  • Santen GmbH
  • Santen Oy
  • Santen Holdings EU BV
  • InnFocus, Inc.
  • Santen, Inc.
  • Star Ab Oy

Competitors

  • Zhaoke Ophthalmology Ltd.
  • Nicox SA
  • EyePoint Pharmaceuticals, Inc.
  • Tarsus Pharmaceuticals, Inc.
  • G-treeBNT Co., Ltd.
  • CHO Pharma, Inc.
  • Satellos Bioscience Inc
Last Updated on 24 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more